Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05977686

Hemoglobin Testing in Pregnant Patients

The project is a prospective observational study aimed to assess and to validate the use of point-of-care hemoglobin testing in pregnancy. Point-of-care hemoglobin testing has the potential to (1) increase access to hemoglobin monitoring in pregnancy in low resource settings, (2) increase availability of hemoglobin monitoring in anemic patients, and (3) provide immediate results for real-time patient counseling and intervention. However, to date, point-of-care hemoglobin testing devices have not yet been studied for use in an ambulatory obstetric population. The Masimo device is a Root Radical 7 Pulse CO-Oximeter, manufactured by Masimo, Inc. This device is non-invasive and placed externally on a patient's finger to generate an estimation of a patient's hemoglobin value. The HemoCue® device is a minimally-invasive device that relies on the finger prick method to get a capillary hemoglobin measurement, and The Rubby is a mobile application based platform that uses a photo of the participants nailbed to estimate hemoglobin values. Participants in this study will be approached at the Obstetrics and Gynecology clinics at George Washington Medical Faculty Associates. Point-of-care hemoglobin measurements will be assessed using the non-invasive Masimo device along with minimally-invasive hemoglobin HemoCue® Hb 801 device and compared to traditional venipuncture hemoglobin testing.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–50 year

Sex eligibility

Female

Study type

Observational

Primary location

George Washington University, Washington D.C., District of Columbia, United States

Loading trial locations.

About this study

This will be a prospective, observational study for which aim to recruit 200 patients over the study period. Patients will be approached at one of the MFA Obstetrics and Gynecology clinics. Once consented, they will be approached at least two time-points during their antenatal care as below:

  • OB new/ first prenatal visit (usually between 12-18 weeks of gestation)
  • OB return visit (usually between 24-28 weeks of gestation)

May need to get more Hb time-points readings (up to five readings) if the patient will be diagnosed with anemia at any of the previously mentioned visits or will be scheduled to have more blood draws during the prenatal care period. At each time-point visit, we plan to talk with the provider of the patient about the study. Then the study protocol and the recruitment process with the patient will be discussed. If the patient consents, the researchers will coordinate with the lab personnel the exact time of the routinely ordered blood draw (as a part of the subject's antenatal care) to determine the appropriate time to get the Hb readings using the devices (preferrably, right before the venipuncture). To obtain the readings, a study research coordinator will apply a disposable probe (Rainbow R1 25 adult adhesive sensor) connected to a Radical-7 co-oximeter sensor on the ring finger of the same arm of the venipuncture, shielded by an opaque covering to eliminate intereference from ambient light to obtain the SpHb reading. In addition, during in the same setting, we will ask for a finger prick capillary sample to get the Hemocue Hb reading as well (the same side will be used). Both readings will be tabulated in a case report form and the standard lab hemoglobin reading will be added to them once received. This is how it will validate the performance of the Masimo and the Hemocue devices with the routine lab test results. Additionally, the researchers will collect demographics, procedure-specific and some antenatal-care variables including vitals, gestational age and the exact date and time of the records at each time point visit, using a well-structured case report form.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant women ages 18-50 years old

Exclusion criteria

  • Patients with hemoglobinopathies (qualitative defects, sickle-cell anemia) and hemoglobin synthesis disorders (quantitative defects such as thalassemia)
  • Patients with peripheral vascular diseases and skin conditions that affect blood vessels in the digit
  • Patients with hyperbilirubinemia

Treatment and study plan

Masimo Root Radical 7 Pulse CO-Oximeter

Device

The Masimo device is non-invasive and placed externally on a patient's finger to generate an estimation of a patient's hemoglobin value.

HemoCue Hb 801

Device

The HemoCue® device is a minimally-invasive device that relies on the finger prick method to get a capillary hemoglobin measurement.

Primary outcomes

  1. Validity of each POC device to detect anemia

    Time frame: Within 6 hours of CBC draw

    Sensitivity, specificity, and positive and negative predictive values for each POC device to detect anemia (Hgb < 11mg/dL) or severe anemia (Hgb < 9mg/dL).

  2. To determine if Point of Care Hemoglobin testing correlates to clinical laboratory results.

    Time frame: 24 - 48 hours to get all test results

    Verify the correlation between point-of-care hemoglobin/ferritin values and the reference laboratory hemoglobin from a CBC (complete blood count) and clinical ferritin test. This aim will help us determine the suitability of the selected testing methods.

Study contacts

Contact information is provided by the study sponsor or research team.

Homa Ahmadzia, MD/MPH

CONTACT

[email protected]

7036226524

Jaclyn Phillips, MD

CONTACT

[email protected]

2027412500

Sponsors and collaborators

Lead sponsor

Inova Health Care Services

Other

Registry information

Official study title

Point-Of-Care Anemia Testing in Pregnant Patients - A Prospective Observational Study

Acronym: AnemiaPOC

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Aug 4, 2023
Registry last updated
Apr 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.